Widely used:Recently Viewed
Clear All
$254 Mln
--
1.31
--
0
-56.73 %
--
0 %
5.01
-3292841
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Solid Biosciences (SLDB)
| 7.17 | -22.31 | 10.22 | 176.47 | -42.93 | -46.88 | -- |
|
BSE Sensex*
| 12.20 | -0.16 | 1.32 | 22.81 | 11.05 | 16.56 | 11.80 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2023
|
2022
|
2021
|
2020
|
2019
|
|
|---|---|---|---|---|---|
|
Solid Biosciences (SLDB)
| 14.13 | -79.50 | -76.91 | 70.34 | -83.40 |
|
S&P Small-Cap 600
| 13.89 | -17.42 | 25.27 | 9.57 | 20.86 |
|
BSE Sensex
| 18.74 | 4.44 | 21.99 | 15.75 | 14.38 |
|
Stock
|
Peer Median
|
||
|---|---|---|---|
loading... |
|||
|
Stock
|
Peer Median
|
||
|---|---|---|---|
loading... |
|||
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Our rating system has guided millions of investors in the past 20 years.
$253.96 Mln
$4.74 Mln
$0.00 Mln
$190.27 Mln
$25.30 Mln
High
$1.81 - 15.05
38,595,200
NASDAQ: SLDB
Charlestown, MA
https://www.solidbio.com
Solid Biosciences Inc., a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular... dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia. It is also developing AVB-401 for the treatment of BAG3-mediated dilated cardiomyopathy; SGT-601 to treat a rare cardiac disease characterized by mutations in the gene that codes for cardiac troponin T protein, which helps coordinate contraction of the heart muscle; SGT-701 for treatment of rare inherited disease characterized by mutations in the RBM20 gene, a cardiac splicing factor that regulates alternative splicing, and codes for RNA binding motif protein 20; and AVB-202-TT to treat Friedreich's ataxia, as well as other drugs for the treatment of cardiac and other diseases. In addition, the company is involved in developing platform technologies, including capsid libraries and dual gene expression, a technology for packaging multiple transgenes into one capsid. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne; and a license agreement with the University of Washington, University of Missouri, and University of Florida. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Charlestown, Massachusetts. Read more
The total asset value of Solid Biosciences Inc (SLDB) stood at $ 246 Mln as on 30-Jun-24
The share price of Solid Biosciences Inc (SLDB) is $6.58 (NASDAQ) as of 04-Oct-2024 16:00 EDT. Solid Biosciences Inc (SLDB) has given a return of -42.93% in the last 3 years.
Solid Biosciences Inc (SLDB) has a market capitalisation of $ 254 Mln as on 04-Oct-2024. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Solid Biosciences Inc (SLDB) is 1.31 times as on 04-Oct-2024, a 58% discount to its peers’ median range of 3.12 times.
Since, TTM earnings of Solid Biosciences Inc (SLDB) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Solid Biosciences Inc (SLDB) and enter the required number of quantities and click on buy to purchase the shares of Solid Biosciences Inc (SLDB).
Solid Biosciences Inc., a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia. It is also developing AVB-401 for the treatment of BAG3-mediated dilated cardiomyopathy; SGT-601 to treat a rare cardiac disease characterized by mutations in the gene that codes for cardiac troponin T protein, which helps coordinate contraction of the heart muscle; SGT-701 for treatment of rare inherited disease characterized by mutations in the RBM20 gene, a cardiac splicing factor that regulates alternative splicing, and codes for RNA binding motif protein 20; and AVB-202-TT to treat Friedreich's ataxia, as well as other drugs for the treatment of cardiac and other diseases. In addition, the company is involved in developing platform technologies, including capsid libraries and dual gene expression, a technology for packaging multiple transgenes into one capsid. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne; and a license agreement with the University of Washington, University of Missouri, and University of Florida. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Charlestown, Massachusetts.
The CEO & director of Mr. Ian F. Smith A.C.A., C.P.A.. is Solid Biosciences Inc (SLDB), and CFO & Sr. VP is Mr. Ian F. Smith A.C.A., C.P.A..
There is no promoter pledging in Solid Biosciences Inc (SLDB).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,034
|
|
|
1,002
|
|
|
998
|
|
|
875
|
| Solid Biosciences Inc. (SLDB) | Ratios |
|---|---|
|
Return on equity(%)
|
-56.73
|
|
Operating margin(%)
|
-2150.59
|
|
Net Margin(%)
|
-1914.93
|
|
Dividend yield(%)
|
0
|
No, TTM profit after tax of Solid Biosciences Inc (SLDB) was $0 Mln.
$-0.12
